57-niaid renews ARLG

NIAID will renew funding ($102.5 million over 7 years) for the Antibacterial Resistance Leadership Group (ARLG), and this time it includes funds for a phage therapy study! The ARLG is a global consortium of scientific experts that leads a clinical research network for antibacterial resistance studies.